Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911641936> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2911641936 endingPage "S23" @default.
- W2911641936 startingPage "S23" @default.
- W2911641936 abstract "The efficacy and safety of mirikizumab (miri), an IL-23p19 antibody, has been evaluated in moderate-to-severe ulcerative colitis (UC) in a phase 2, randomized, double-blind, placebo (pbo)-controlled trial (AMAC, NCT02589665; presented at DDW 2018). Miri demonstrated efficacy on multiple measures in the 12-week induction treatment. This analysis evaluated the effects of miri on health-related quality of life (HRQoL) in patients with UC. Patients with moderate-to-severe UC (Mayo score 6-12; Endoscopic subscore ≥2) were randomised 1:1:1:1 to receive intravenous miri 50 mg (N=63) or 200 mg (N=62), both with possible exposure-based increase (2-12 fold or 1.5-3 fold, respectively, to a maximum 600 mg dose), or fixed dose miri 600 mg (N=61), or pbo (N=63) at Weeks 0, 4, and 8. Patients could receive oral 5-aminosalicylic acid (ASA), corticosteroids (≤20 mg/d prednisone equivalent), or thiopurines; must have failed ≥1 conventional UC therapy; and were either naïve to or had prior exposure to biologics. HRQoL was measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) and evaluated using a mixed model repeated measures (MMRM) analysis. The percentage of patients at Week 12 with clinical response,1endoscopic healing,2 IBDQ total score ≥170, and IBDQ improvement ≥16 were also assessed. As early as Week 4, and continuing through Week 12, IBDQ total scores improved versus baseline and versus pbo across all miri groups except miri 50 mg versus pbo at Week 12 (Table). At Week 12, the proportions of patients with IBDQ total score ≥170 were higher with miri 50 mg, 200 mg, and 600 mg than pbo (44%, 56%, 54% vs. 30%, respectively) and higher proportions of miri- than pbo-treated patients had improvements ≥16 points from baseline in IBDQ total score. At Week 12, clinical response and endoscopic healing rates were greater for miri 50 mg and 200 mg versus pbo (Table). Induction treatment with miri was associated with HRQoL improvement in patients with UC. These are the first data evaluating the effects of an IL-23p19 antibody on the HRQoL of patients with UC." @default.
- W2911641936 created "2019-02-21" @default.
- W2911641936 creator A5018781693 @default.
- W2911641936 creator A5029428855 @default.
- W2911641936 creator A5032150391 @default.
- W2911641936 creator A5032504505 @default.
- W2911641936 creator A5033387742 @default.
- W2911641936 creator A5048464948 @default.
- W2911641936 creator A5057899912 @default.
- W2911641936 creator A5062240444 @default.
- W2911641936 creator A5063855371 @default.
- W2911641936 creator A5083568631 @default.
- W2911641936 creator A5084744696 @default.
- W2911641936 date "2019-02-01" @default.
- W2911641936 modified "2023-10-17" @default.
- W2911641936 title "P033 EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY" @default.
- W2911641936 doi "https://doi.org/10.1053/j.gastro.2019.01.085" @default.
- W2911641936 hasPublicationYear "2019" @default.
- W2911641936 type Work @default.
- W2911641936 sameAs 2911641936 @default.
- W2911641936 citedByCount "1" @default.
- W2911641936 countsByYear W29116419362020 @default.
- W2911641936 crossrefType "journal-article" @default.
- W2911641936 hasAuthorship W2911641936A5018781693 @default.
- W2911641936 hasAuthorship W2911641936A5029428855 @default.
- W2911641936 hasAuthorship W2911641936A5032150391 @default.
- W2911641936 hasAuthorship W2911641936A5032504505 @default.
- W2911641936 hasAuthorship W2911641936A5033387742 @default.
- W2911641936 hasAuthorship W2911641936A5048464948 @default.
- W2911641936 hasAuthorship W2911641936A5057899912 @default.
- W2911641936 hasAuthorship W2911641936A5062240444 @default.
- W2911641936 hasAuthorship W2911641936A5063855371 @default.
- W2911641936 hasAuthorship W2911641936A5083568631 @default.
- W2911641936 hasAuthorship W2911641936A5084744696 @default.
- W2911641936 hasConcept C126322002 @default.
- W2911641936 hasConcept C142724271 @default.
- W2911641936 hasConcept C159110408 @default.
- W2911641936 hasConcept C168563851 @default.
- W2911641936 hasConcept C1862650 @default.
- W2911641936 hasConcept C204787440 @default.
- W2911641936 hasConcept C27081682 @default.
- W2911641936 hasConcept C2778260677 @default.
- W2911641936 hasConcept C2778720950 @default.
- W2911641936 hasConcept C2779134260 @default.
- W2911641936 hasConcept C2779951463 @default.
- W2911641936 hasConcept C2780479503 @default.
- W2911641936 hasConcept C71924100 @default.
- W2911641936 hasConcept C90924648 @default.
- W2911641936 hasConceptScore W2911641936C126322002 @default.
- W2911641936 hasConceptScore W2911641936C142724271 @default.
- W2911641936 hasConceptScore W2911641936C159110408 @default.
- W2911641936 hasConceptScore W2911641936C168563851 @default.
- W2911641936 hasConceptScore W2911641936C1862650 @default.
- W2911641936 hasConceptScore W2911641936C204787440 @default.
- W2911641936 hasConceptScore W2911641936C27081682 @default.
- W2911641936 hasConceptScore W2911641936C2778260677 @default.
- W2911641936 hasConceptScore W2911641936C2778720950 @default.
- W2911641936 hasConceptScore W2911641936C2779134260 @default.
- W2911641936 hasConceptScore W2911641936C2779951463 @default.
- W2911641936 hasConceptScore W2911641936C2780479503 @default.
- W2911641936 hasConceptScore W2911641936C71924100 @default.
- W2911641936 hasConceptScore W2911641936C90924648 @default.
- W2911641936 hasIssue "3" @default.
- W2911641936 hasLocation W29116419361 @default.
- W2911641936 hasOpenAccess W2911641936 @default.
- W2911641936 hasPrimaryLocation W29116419361 @default.
- W2911641936 hasRelatedWork W1576589857 @default.
- W2911641936 hasRelatedWork W1998231725 @default.
- W2911641936 hasRelatedWork W2086203819 @default.
- W2911641936 hasRelatedWork W2117513967 @default.
- W2911641936 hasRelatedWork W2149739154 @default.
- W2911641936 hasRelatedWork W2469858376 @default.
- W2911641936 hasRelatedWork W3204746024 @default.
- W2911641936 hasRelatedWork W46359855 @default.
- W2911641936 hasRelatedWork W79702259 @default.
- W2911641936 hasRelatedWork W3142836177 @default.
- W2911641936 hasVolume "156" @default.
- W2911641936 isParatext "false" @default.
- W2911641936 isRetracted "false" @default.
- W2911641936 magId "2911641936" @default.
- W2911641936 workType "article" @default.